β1-6 branching of cell surface glycoproteins may contribute to uveal melanoma progression by up-regulating cell motility

Molecular Vision

Volumn 14, Issue , 2008, Pages 625-636

  Przybyło, Małgorzata ^a   Pocheć, Ewa ^a   Link Lenczowski, Paweł ^a   Lityńska, Anna ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; FIBRONECTIN; FIBRONECTIN RECEPTOR; GLYCAN; GLYCOPROTEIN; INTEGRIN; MANNOSE; MESSENGER RNA; N ACETYLGLUCOSAMINE; OLIGOSACCHARIDE; VERY LATE ACTIVATION ANTIGEN 3; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR; MEMBRANE PROTEIN;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CATALYSIS; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CELL REGENERATION; CELL SURFACE; CONTROLLED STUDY; FLOW CYTOMETRY; GLYCOSYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UVEA MELANOMA; WOUND HEALING; CELL LINE; CELL MEMBRANE; CELL MOTION; CHEMICAL STRUCTURE; CHEMISTRY; DISEASE COURSE; HUMAN; MELANOMA; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SKIN TUMOR; UVEA TUMOR;

CELL ADHESION; CELL LINE; CELL MEMBRANE; CELL MOVEMENT; DISEASE PROGRESSION; FIBRONECTINS; GLYCOSYLATION; HUMANS; INTEGRINS; MELANOMA; MEMBRANE GLYCOPROTEINS; MOLECULAR STRUCTURE; OLIGOSACCHARIDES; RECEPTORS, FIBRONECTIN; SKIN NEOPLASMS; UVEAL NEOPLASMS;

EID: 42349102916     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Damato B, Disease and 'dis-ease' in patients with uveal melanoma. Br J Ophthalmol 2000; 84:343-4.
2. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110:962-5.
3. McLean IW. The biology of haematogencus metastasis in human uveal malignant melanoma. Virchows Arch A Pathol Anat Histopathol 1993; 422:433-7.
4. Shields JA, Shields CL, Donoso LA. Management of posterior uveal melanoma. Surv Ophthalmol 1991; 36:161-95.
5. De Croock L, Verbraeken H. Metastatic uveal melanoma: diagnosis and treatment: a literature review. Bull Soc Belge Ophtalmol 2002; 286:59-63.
6. Singh AD, Borden EC. Metastatic uveal melanoma. Ophthalmol Clin North Am 2005; 18:143-50.
7. Mahoney MC, Burnett WS, Majerovics A, Tanenbaum H. The epidemiology of ophthalmic malignancies in New York State. Ophthalmology 1990; 97:1143-7.
8. McCarthy JM, Rootman J, Horsman D, White VA. Conjunctival and uveal melanoma in the dysplastic nevus syndrome. Surv Ophthalmol 1993; 37:377-86.
9. Chana JS, Wilson GD, Cree IA, Alexander RA, Myatt N, Neale M, Foss AJE, Hungerford JL. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J. Ophthalmol 1999; 83:110-4.
10. Niederkorn JY. Immunoregulation of intraocular tumours. Eye 1997; 11:249-54.
11. Verbik DJ, Murray TG, Tran JM, Ksander BR. Melanomas that develop within the eye inhibit lymphocyte proliferation. Int J Cancer 1997; 73:470-8.
12. Ksander BR, Geer DC, Chen PW, Salgaller ML, Rubsamen P, Murray TG. Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes. Curr Eye Res 1998; 17:165-73.
13. Albert DM, Ryan LM, Borden EC. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol 1996; 114:107-8.
14. Albert DM. The ocular melanoma story. Am J Ophthalmol 1997; 123:729-41.
15. Stetler-Stevenson WG. The role of matrix metaloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am 2001; 10:383-92.
16. Laidler P, Litynska A, Hoja-Lukowicz D, Labedz M, Przybylo M, Ciolczyk-Wierzbicka D, Pochec E, Trebacz E, Kremser E. Characterization of glycosylation and adherent properties of melanoma cell lines. Cancer Immunol Immunother 2006; 55:112-8.
17. Morgan Parkes JH. Metastases: mechanisms, pathways, and cascades. AJR Am J Roentgenol 1995; 164:1075-82.
18. Engers R, Gabbert HE. Mechanisms of tumor metastasis: cell biological aspects and clinical implications. J Cancer Res Clin Oncol 2000; 126:682-92.
19. Clezardin P. Recent insight into the role of integrins in cancer metastasis. Cell Mol Life Sci 1998; 54:541-8.
20. Nesbit M, Herlyn M. Adhesion receptors in human melanoma progression. Invasion Metastasis 1994; 14:131-46.
21. Fidler IJ. Molecular biology of cancer: invasion and metastasis. In: De Vita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven Publisherrs; 1997. p. 135-52.
22. 33 integrin and intracellular adhesion molecule-1 in cutaneous malignant melanoma lesion. Cancer Res 1997; 57:1554-60.
23. Jiang WG, Puntis MC, Hallett MB. Molecular and celluler basis of cancer invasion and metastasis: implications for treatment. Br J Surg 1994; 81:1576-90.
24. De Waard-Siebinga I, Blom DJ, Griffioen M, Schrier PI, Hoogendoorn E, Beverstock G, Danen EH, Jager MJ. Establishment and characterization of an uveal-melanoma cell line. Int J Cancer 1995; 62:155-61.
25. Real LM, Jimenez P, Cantón J, Kirkin A, García A, Abril E, Zeuthen J, Ruiz-Cabello F, Garrido F. In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele. Int J Cancer 1998; 75:317-23.
26. Aubert C, Rouge F, Galindo JR. Tumorigenicity of human malignant melanocytes in nude mice in relation to their differentiation in vitro. J Nad Cancer Inst 1980; 64:1029-40.
27. Laidler P, Gil D, Pituch-Noworolska A, Ciołczyk D, Ksiazek D, Przybyło M, LityńskaA. Expression of beta1-integrins and N-cadherin in bladder cancer and melanoma cell lines. Acta Biochim Pol 2000; 47:1159-70.
28. Chakraborty AK, Pawelek J, Ikeda Y, Kolesnikova N, Funasaka Y, Ichibashi M, Taniguchi N. Fusion hybrids with macrophage and melanoma cells up-regulate N-acetylglucosaminyltransferase V, β1-6 branching, and metastasis. Cell Growth Differ 2001; 12:623-30. [
29. 1 integrin. Oncogene 2003; 22:7137-45.
30. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-5.
31. Peterson GL. A symplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 1977; 83:346-56.
32. Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv Cancer Res 1999; 76:1-20.
33. Kawano T, Takasaki S, Tao T-W, Kobata A. Altered glycosylation of β1 integrins associated with reduced adhessiveness to fibronectin and laminin. Int J Cancer 1993; 53:91-6.
34. 1 subunits and concomitant loss of fibronectin binding activity. J Biol Chem 1994; 269:12325-31.
35. Veiga SS, Chammas R, Cella N, Brentani RR. Glycosylation of β1 integegrins in B16-F10 mouse melanoma cells as determinant of differential binding and aquisition of biological activity. Int J Cancer 1995; 61:420-4.
36. Zheng M, Hakomori S. Soluble fibronectin interaction with cell surface and extracellular matrix is mediated by carbohydrate-to-carbohydrate interaction. Arch Biochem Biophys 2000; 374:93-9.
37. 1 integrin clustering and stimulates cell migration. Cancer Res 2002; 62:683745.
38. 1 changes with melanoma progression. Biochim Biophys Acta 2003; 1643:113-23.
39. Couldrey C, Green JE. Metastases: the glycan connection. Breast Cancer Res 2000; 2:321-3.
40. Cummings RD, Kornfeld S. Characterization of the structural determinants required for the high affinity interaction of asparagine-linked oligosaccharides with immobilized Phaseolus vulgaris leukoagglutining and erythroagglutining lectins. J Biol Chem 1982; 257:112304.
41. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim Biophys Acta 1999; 1473:21-34.
42. 3 subunit with tumor progression. Cancer Res 1990; 50:6757-64.
43. Klein CE, Steinmayer T, Kaufmann D, Weber L, Brocker EB. Identification of a melanoma progression antigen as integrin VLA-2. J Invest Dermatol 1991; 96:281-4.
44. Natali PG, Nicotra MR, Cavaliere R, Giannarelli D, Bigotti A. Tumor progression in human malignant melanoma is associated with changes in alpha 6/beta 1 laminin receptor. Int J Cancer 1991; 49:168-72.
45. Kuphal S, Bauer R, Bosserhoff A-K. Integrin signaling in malignant melanoma. Cancer Metastasis Rev 2005; 24:195-222.
46. ten Berge PJ, Danen EH, van Muijen GN, Jager MJ, Ruiter DJ. Integrin expression in uveal melanoma differs from cutaneous melanoma. Invest Oplathalmol Vis Sci 1993; 34:3635-40.
47. Marshall JF, Rutherford DC, Happerfield L, Hanby A, McCartney AC, Newton-Bishop J, Hart IR. Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas. Br J Cancer 1998; 77:522-9.
48. Demetriou M, Nabi IR, Coppolino M, Dedhar S, Dennis JW. Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V. J Cell Biol 1995; 130:383-92.
49. Litynska A, Przybylo M, Pochec E, Kremser E, Hoja-Łukowicz D, Sulowska U. Does glycosylation of melanoma cells influence their interactions with fibronectin? Biochimie 2006; 88:527-34.
50. Przybyło M, Martuszewska D, Pocheć E, Hoja-Łukowicz D, Lityńska A. Identification of proteins bearing beta1-6 branched N-glycans in human melanoma cell lines from different progression stages by tandem mass spectrometry analysis. Biochim Biophys Acta 2007; 1770:1427-35.
51. Taniguchi N, Miyoshi E, Jianguo G, Honke K, Matsumoto A. Decoding sugar function by identifying target glycoproteins. Curr Opin Struct Biol 2006; 16:561-6.
52. Palecek SP, Loftus JC, Ginsberg MH, Lauffenburger DA, Horwitz AF. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 1997; 385:537-40.
53. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64:327-36.
54. Juliano RL, Varner JA. Adhesive molecules in cancer: the role of integrins. Curr Opin Cell Biol 1993; 5:812-8.
55. Fernandes B, Sagman U, Auger M, Demetrio M, Dennis JW. β1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res 1991; 51:718-23.
56. Wojciechowicz DC, Park PY, Datta RV, Paty PB. CEA is the major PHA-L reactive glycoprotein in colon carcinoma cell lines and tumors: relationship between K-ras activation and β1-6-branching of N-linked carbohydrate on CEA. Biochem Biophys Res Commun 2000; 273:147-53.
57. Humphries MJ, Matsumoto K, White SL, Olden K. Oligosacharide modification by swainsonine treatment inhibits pulmonary colonization by B16-F10 murine melanoma cells. Proc Natl Acad Sci USA 1986; 83:1752-6.
58. Seberger PJ, Chaney WG. Control of metastasis by Asn-linked, β1-6 branched oligosaccharides in mouse mammary cancer cells. Glycobiology 1999; 9:235-41.
59. Cornil I, Kerbel RS, Dennis JW. Tumor cell surface βl-4-linked galactose binds to lectin(s) on microvascular endothelial cells and contribute to organ colonization. J Cell Biol 1990; 111:773-81.
60. Gorelik E, Galili U, Raz A. On the role of cell surface carbohydrates and their b4nding proteins (lectins) in tumor metastasis. Cancer Metastasis Rev 2001; 20:245-77.
61. Krishnan V, Bane SM, Kawle PD, Naresh KN, Kalraiya RD. Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clin Exp Metastasis 2005; 22:11-24.
62. ReddyBVKalraiyaRDSialilIated beta1,6 branched N-oligosaccharides modulate adhesion, chemotaxis and motility of melanoma cells: Effect on invasion and spontaneous metastasis properties. Biochim Biophys Acta200617601393402Epub 2006 May 23
63. Guo HB, Liu F, Zhao JH, Chen HL. Down-regulation of N-acetylglucosaminyltransferase V by tumorigenesis- or metastasis-suppressor gene and its relation to metastatic potential of human hepatocarcinoma cells. J Cell Biochem 2000; 79:370-85.
64. +-ATPase. J Biol Chem 2001; 276:48451-46457.
65. Guo HB, Shen ZH, Huang CX, Ma J, Huang Y, Chen HL. Modulation of the basal activity of N-acetylglucosaminyltransferase V by phoshatidylinositol-3-kinase / protein kinase B signalling pathway in human hepatocarcinoma, cells. Glycocon J 2000; 17:315-22.
66. Guo HB, Jiang AL, Ju TZ, Chen HL. Opposing changes in N-acetylyltransferase-V and -III during the cell cycle and all-trans retinoic acid treated of hepatocarcinoma cell line. Biochim Biophys Acta 2000; 1495:297-307.
67. Do KY, Fregien N, Pierce M, Cummings RD. Modification of glycoproteins by N-acetylglucosaminyltransferase V is greatly influenced by accessibility of the enzyme to oligosaccharide acceptors. J Biol Chem 1994; 269:23456-64.
68. Yoshimura M, Nishikawa A, Ihara Y, Taniguchi S, Tauiguchi N. Suppression of lung ffietastasis of B16 mouse melanoma by N-acetylglucosaminyltransferase III gene transfection. Proc Natl Aca4 Sci USA 1~95; 92:8754-8.
69. Yoshimura M, Ihara Y, Matsuzawa Y, Taniguchi N. Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis. J Biol Chem 1996; 271:13811-5.
70. Gu J, Taniguchi N. Regulation of integrin functions by N-glycans. Glycoconj J 2004; 21:9-15.
71. 1 reduces-ligand binding and down-regulates celf adhesion and cell migration. J Biol Chem 2004; 279:19747-54.